Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trial offers early test case for personalized medicine.

× No keyword cloud information.

5 in total

1. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Authors: Chandra Bartholomeusz; Tetsuro Oishi; Hitomi Saso; Ugur Akar; Ping Liu; Kimie Kondo; Anna Kazansky; Savitri Krishnamurthy; Jangsoon Lee; Francisco J Esteva; Junzo Kigawa; Naoto T Ueno
Journal: Mol Cancer Ther Date: 2011-12-05 Impact factor: 6.261

2. The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Authors: Shan Muhammad; Zheng Jiang; Zheng Liu; Kavanjit Kaur; Xishan Wang
Journal: J Gastrointest Oncol Date: 2013-03

3. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors: S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531

Review 4. Pharmacogenetics and stroke.

Authors: James F Meschia
Journal: Stroke Date: 2009-09-17 Impact factor: 7.914

Review 5. Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Authors: F Wei; J Yan; D Tang
Journal: Curr Med Chem Date: 2011 Impact factor: 4.530

5 in total